Incstar Corp. on Wednesday said it has completed a NorthAmerican distribution agreement for certain of Centocor Inc.'stumor marker immunodiagnostic tests.
The agreement grants Incstar (AMEX:ISR) of Stillwater, Minn.,semi-exclusive sales and marketing rights to Centocor's CA 125RIA Serum Tumor Marker kit and other kits receivingregulatory approval, in exchange for cash payments totaling$2.7 million over the next two years.
CA 125 is sold in the United States as an ovarian cancer testprior to second-look surgery.
Three other Centocor kits are currently sold in Europe andJapan. The Malvern, Pa., company (NASDAQ:CNTO) intends toapply for U.S. approval of these kits.
Hybritech Inc. already distributes CA 125. Under the terms ofthe Incstar agreement, only one other third party maydistribute the kits.
(c) 1997 American Health Consultants. All rights reserved.